Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.17+0.16 (+2.66%)
At close: 04:00PM EST
6.08 -0.09 (-1.46%)
After hours: 05:57PM EST
Advertisement
Sign in to post a message.
  • b
    bill
    We are down almost 20% in a week! Any thoughts on why? I see nothing negative….
  • m
    m
    Hope u followed the advice of the premier blue chip analyst at Raymond James on Nov 4, 2021 with their outperform rating and price target of $15.
  • d
    dillois
    Don't get me wrong, I love the price action, but last news was an insider selling $15M and since this goes up significantly. Any insight besides overall market moving? Maybe short covering before EOY?
  • W
    Whistleblower
    @dillois @Christopher if your long then why couldn't you read the SEC filing before calling it an insider sale?
    not just that, now you turned your false information into a fact and wondered why the stock went up.
    don't you think you need to first confirm your assumptions before drawing conclusions?
  • W
    Whistleblower
    Watch out for Jan, Feb M&A announcements.
    specifically players in JNCE space are likely targets for approx 2B purchases.
    I would hate to see JNCE sold for 2B, but 5 times current price is a good thing. 👍
  • M
    Mark
    Up pre-market .49 cents on a volume of 4 shares.
  • W
    Whistleblower
    whole biotechnology has been down and going down for weeks now.
    it's the usual Biotech cycle and strongly.spikes up by end of December and January.
    add M&A activity in Jan & Feb where most price rises happen.

    knowledge helps buddy Michael.
  • M
    Matthew
    remember that 100k shares can make this move a lot. we want to confirm moves of more volume.
  • M
    Matthew
    continued sales from form 4 1.9 mil is a lot when you have 70 mil shares and only 300k trade in a day
  • M
    Matthew
    11/16 it was reported that third rock capital continued to sell the shares of its partners. most recently 2 form 4s were presented to detail the sale of 1.9 million shares initiated on 11/12/21. This is the reason for recent weakness and it is not due to company performance so much so as it its the de-risking and distribution by third rock capital who i can only assume handles the shares of board members and company members with lines of credit to avoid real insider sales. Remember that recently new board members and management were provided derivative options for coming on board. Keep your eyes peeled incase a good portion of the 1.9 million shares sold are made in an institution to institution transaction what bumps anyone's holdings over 5% reporting requirment.
  • M
    Matthew
    What a reaction today to the low volume drop. Things are getting interesting. the chart is in indecision land but my thesis still points up.
  • b
    bill
    Was hoping this thing would hold at 7 but that’s not happening. Looks like we’re headed back into the 5’s
  • M
    Matthew
    down trend co firmed and will likely continue for another week. where it reverses will tell us a lot about the outlook and how stable to institutional holder are in the face of the 1.9 million in share sales dated as initiated 11/12
  • M
    Matthew
    still seeing some big supportive trades 8.5 to 9.0 gobble those shares and keep them out of the market
  • m
    momr
    Faith is a higher faculty than reason. http://dataunion.tistory.com/19679 Sweat_will_get_you_change.
  • m
    michael
    I finally met my average… should have sold it last time that happened. Good luck to all…. Something good should happen now
  • D
    DreamMaker
    Why the drip today?
  • J
    Joe
    With a positive earnings report we are on our way to $11.
  • W
    WallStreet
    I put this on ST, twitter and SA.
    Biomarker: Vopra works best by blocking ICOS hi. Previous efforts to benefit patients gave mixed results from ICONIC study as A. population mostly lacked ICOS HI cells in Tumor environment. B. Most patients show Depleted Tcells. JNCE has shown how patients with ICOS hi population can greatly benefit from this therapy EVEN if they had been exposed to IO therapies before. Really even 4th line patients were experiencing some response (RR) So with Biomarker, we will only identify patients with potential ICOS HI cells, thereby greatly increasing the OS of the patient, and of course efficacy of VOPRA. Just LOVE this news, can take this small company into a major league of Bio companies.

    2. It's actually VOPRA that was found to induce ICOS in Tumor micro environments (TME) and not Yervoy or Ipi. PD1 or/AND CTLA4 is only a mechanism to increase T-cell population in TME. Therefore Vopra can be used in Various ( i emphasize various) cancer types. The application has now grown many fold.

    3. PD1 and Partnership / BO : Not many big companies can claim PD1 drug on their pipeline. Big ones like BMY, Merc and handful of others have it. Our Tiny Jounce has it and fun fact: it's actually JNCE owner James who discovered PD1 and CTLA4.
    JTX-4014 PD1 is the new generation PD1 and Opdivo and others are more like the first gen PD1. Any company that is looking to get a PD1 can PARTNER with JNCE to get a 2nd gen PD1 going for them. This makes JNCE not just a likely candidate for partnership for also Buyout sooner than later. Too early, but that's PD1 for you.

    4. They have drugs in development stages, especially the Jtx-1811 T-reg one. This is going to be big.
    when combined with Vopra and depending on the patient type, incorporating T-reg method or by decreasing T-Reg cells, there is agreat efficacy to be gained if toxicity is well managed. There are patients who display less toxicity to T-reg depletion than others. so works for selective patients.

    5. CELG/BMW partnership and Cash. BMY will continue to provide milestone cash payments. Other discovery programs under stromal, macrophage and my fav T-Reg can easily get partnerships going. This is HOT space.
  • W
    Whistleblower
    Matthew I think ER was great. What do you think?
Advertisement
Advertisement